PMCC Resources

Here are the staff publications for February 2017, compiled March 1st.

  1. Alchin DR, Murphy D, Lawrentschuk N. Predicting the risk of positive surgical margins following robotic-assisted radical prostatectomy. Minerva Urologica e Nefrologica 2017;69:56-62.
  2. Bower NI, Vogrin AJ, Le Guen L, et al. Vegfd modulates both angiogenesis and lymphangiogenesis during zebrafish embryonic development. Development 2017;144:507-18.
  3. Buchanan DD, Clendenning M, Rosty C, et al. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts. Journal of Gastroenterology and Hepatology 2017;32:427-38.
  4. Cameron LB, Jiang DH, Moodie K, Mitchell C, Solomon B, Parameswaran BK. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. Cancer Imaging 2017;17:7.
  5. Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast 2017;31:244-59.
  6. Chan KL, van der Weyden C, Khoo C, et al. Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leukemia & Lymphoma 2017;58:996-8.
  7. Chun K, Capitanio JP, Lamkin DM, Sloan EK, Arevalo JM, Cole SW. Social regulation of the lymph node transcriptome in rhesus macaques (Macaca mulatta). Psychoneuroendocrinology 2017;76:107-13.
  8. Dall GV, Vieusseux JL, Korach KS, et al. SCA-1 Labels a Subset of Estrogen-Responsive Bipotential Repopulating Cells within the CD24+ CD49fhi Mammary Stem Cell-Enriched Compartment. Stem Cell Reports 2017;8:417-31.
    Dickinson M, Irving L, Hofman M. Early warning signs: FDG-PET to diagnose bleomycin toxicity. Leukemia & Lymphoma 2017;58:1016-8.
  9. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncology 2017;18:241-50.
    El-Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. European Journal of Cancer 2017;75:195-203.
  10. Emery JD, Jefford M, King M, et al. ProCare Trial: a phase II randomized controlled trial of shared care for follow-up of men with prostate cancer. BJU International 2017;119:381-9.
  11. Fisher OM, Lord SJ, Falkenback D, Clemons NJ, Eslick GD, Lord RV. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. Gut 2017;66:399-410.
  12. Goldblatt C, Khumra S, Booth J, Urbancic K, Grayson ML, Trubiano JA. Poor reporting and documentation in drug-associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis - Lessons for medication safety. British Journal of Clinical Pharmacology 2017;83:224-6.
  13. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 2017;129:553-60.
  14. Hertzberg M, Gandhi MK, Trotman J, et al. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica 2017;102:356-63.
  15. Imberti C, Terry SY, Cullinane C, et al. Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of alphavbeta3 Integrin Expression with Gallium-68. Bioconjugate Chemistry 2017;28:481-95.
  16. Jung M, Russell AJ, Liu B, et al. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Research 2017;77:971-81.
  17. Kar SP, Adler E, Tyrer J, et al. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer 2017;116:524-35.
  18. Kee D, McArthur G. Immunotherapy of melanoma. European Journal of Surgical Oncology 2017;43:594-603.
  19. Kenealy M, Patton N, Filshie R, et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leukemia & Lymphoma 2017;58:298-307.
  20. Kinnane NA, Piper AJ, Jefford M. How will cancer survivors use survivorship care plans? Acta Oncologica 2017;56:183-9.
  21. Kist JW, de Keizer B, Hoekstra OS, Vogel WV. Reply: THYROPET Study: Is It Biology or Technology That Is the Issue? Journal of Nuclear Medicine 2017;58:354-5.
  22. Kong G, Callahan J, Hofman MS, et al. High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2017;44:476-89.
  23. Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and Salvage Surgery Following "Watch and Wait" for Rectal Cancer after Neoadjuvant Therapy: A Systematic Review. Diseases of the Colon and Rectum 2017;60:335-45.
  24. Lamb AD, Zargar H, Murphy DG, Corcoran NM, Hovens CM. Disrupting the Status Quo in Prostate Cancer Diagnosis. European Urology 2017;71:193-4.
  25. Lambertini M, Falcone T, Unger JM, Phillips KA, Del Mastro L, Moore HC. Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. Journal of Clinical Oncology 2017;35:804-5.
  26. Lieberman L, Barod R, Dalela D, et al. Use of Main Renal Artery Clamping Predominates Over Minimal Clamping Techniques During Robotic Partial Nephrectomy for Complex Tumors. Journal of Endourology 2017;31:149-52.
  27. Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology 2017;49:141-55.
  28. Matheson JA, Te Marvelde L, Mailer S, et al. Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Research 2017;27:43-9.
  29. Murphy DG, Hofman M, Lawrentschuk N, Maurer T. Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer. BJU International 2017;119:194-5.
  30. Nolan E, Lindeman GJ, Visvader JE. Out-RANKing BRCA1 in Mutation Carriers. Cancer Research 2017;77:595-600.
    Oates R, Brown A, Tan A, et al. Real-time Image-guided Adaptive-predictive Prostate Radiotherapy using Rectal Diameter as a Predictor of Motion. Clinical Oncology (R Coll Radiol) 2017;29:180-7.
  31. Papa N, Perera M, Hofman MS, Bolton D, Lawrentschuk N. Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926-37. European Urology 2017;71:e66-e7.
  32. Pattison DA, Hicks RJ. THYROPET Study: Is It Biology or Technology That Is the Issue? Journal of Nuclear Medicine 2017;58:354.
  33. Phillips C, Jeffree R, Khasraw M. Management of breast cancer brain metastases: A practical review. Breast 2017;31:90-8.
  34. Rebello RJ, Pearson RB, Hannan RD, Furic L. Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes 2017;8.
  35. Rogers TM, Arnau GM, Ryland GL, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Scientific Reports 2017;7:42259.
  36. Ryan J, Akhurst T, Lynch AC, Michael M, Heriot AG. Neoadjuvant 90 Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report. ANZ Journal of Surgery 2017;87:92-3.
  37. Schiavina R, Novara G, Borghesi M, et al. PADUA and R.E.N.A.L. nephrometry scores correlate with perioperative outcomes of robot-assisted partial nephrectomy: analysis of the Vattikuti Global Quality Initiative in Robotic Urologic Surgery (GQI-RUS) database. BJU International 2017;119:456-63.
  38. Schmiegel W, Scott RJ, Dooley S, et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Molecular Oncology 2017;11:208-19.
  39. Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncology 2017;18:230-40.
  40. Shortt J, Ott CJ, Johnstone RW, Bradner JE. A chemical probe toolbox for dissecting the cancer epigenome. Nature Reviews Cancer 2017;17:160-83.
  41. Spicer JA, Miller CK, O'Connor PD, et al. Benzenesulphonamide inhibitors of the cytolytic protein perforin. Bioorganic & Medicinal Chemistry Letters 2017;27:1050-4.
  42. Takeda K, Nakayama M, Hayakawa Y, et al. IFN-gamma is required for cytotoxic T cell-dependent cancer genome immunoediting. Nature Communications 2017;8:14607.
  43. Tam CS, Kimber T, Seymour JF. Ibrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemia. British Journal of Haematology 2017;176:829-31.
  44. Teh BW, Harrison SJ, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. European Journal of Haematology 2017;98:149-53.
  45. Tesson S, Richards I, Porter D, et al. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile? Breast 2017;31:233-40.
  46. Touati N, Tryfonidis K, Caramia F, et al. Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumour suppressor in breast cancer. European Journal of Cancer 2017;72:95-102.
  47. Vinod SK, Lim K, Bell L, et al. High-risk CTV delineation for cervix brachytherapy: Application of GEC-ESTRO guidelines in Australia and New Zealand. Journal of Medical Imaging and Radiation Oncology 2017;61:133-40.
  48. Ye YH, Seleznev A, Flores HA, Woolfit M, McGraw EA. Gut microbiota in Drosophila melanogaster interacts with Wolbachia but does not contribute to Wolbachia-mediated antiviral protection. Journal of Invertebrate Pathology 2017;143:18-25.

Health Sciences Library [MAP]

PO Royal Melbourne Hospital


Phone: (03) 9342 8617; Fax: (03) 9342 8615

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Learning Resource Centre [MAP]

Level 7A, Peter MacCallum Cancer Centre

305 Grattan Street


Phone: (03) 8559 7194


Library Manager

Susan Monaghan;

Phone: (03) 9342 7346

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Health Sciences Library (RMH Building)

Hours (February - November):

Monday - Thursday: 8.30am - 6pm

Friday: 8.30am - 5pm

Summer Hours (December - January):

Monday - Friday: 8:30am - 5pm 

Learning Resource Centre (Peter MacCallum Building)

Staffed Hours (January - December):

Monday - Thursday: 10am - 2pm